



UNIVERSITI PUTRA MALAYSIA

**THE NUCLEOCAPSID PROTEIN OF NEWCASTLE DISEASE VIRUS
AS A CARRIER FOR THE VP1 POLYPEPTIDES OF ENTEROVIRUS**

71

LALITA AMBIGAI SIVASAMUGHAM.

FBSB 2005 10



**THE NUCLEOCAPSID PROTEIN OF NEWCASTLE DISEASE VIRUS AS A
CARRIER FOR THE VP1 POLYPEPTIDES OF ENTEROVIRUS 71**

By

LALITA AMBIGAI SIVASAMUGHAM

**Thesis submitted to the School of Graduate Studies, Universiti Putra
Malaysia, in Fulfilment of the Requirements for the Degree of Master of
Science**

October 2005



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in
fulfilment of the requirement for the degree of Master of Science

**THE NUCLEOCAPSID PROTEIN OF NEWCASTLE DISEASE VIRUS AS A
CARRIER FOR THE VP1 POLYPEPTIDES OF ENTEROVIRUS 71**

By

LALITA AMBIGAI SIVASAMUGHAM

October 2005

Chairman: Professor Datin Khatijah Yusoff, PhD

Faculty: Biotechnology and Biomolecular Sciences

Human enterovirus 71 (EV71) is an important human enterovirus which belongs to the *Enterovirus* genus of the *Picornaviridae* family. Large outbreaks of EV71 have been associated with severe central nervous disease (CNS) manifestations including the hand, foot and mouth disease (HFMD). To date, there is no effective antiviral drug available to treat the infections. Therefore, the development of an effective vaccine is considered as one of the best choice to prevent the diseases caused by EV71.

The VP1 protein which is the most immunogenic capsid protein of EV71, can be used in the development of subunit EV71 vaccines. The complete VP1 protein of EV71 was truncated into six regions and fused to the full length nucleocapsid protein (NPfl) and truncated NP (NPt; which lacks 20% amino acids from its C-terminal end). Western blot analysis using rabbit anti-VP1 serum showed that the N-terminal region of the VP1 protein contained a major antigenic region. Of all

the recombinant NP proteins, the ones carrying truncated VP1 protein, VP1₁₋₁₀₀ were efficiently expressed in *Escherichia coli* system. Electron microscopic analysis of the purified NPt-VP₁₋₁₀₀ revealed that this protein predominantly self-assembled into intact ring-like structure whereas NPfl-VP₁₋₁₀₀ showed disrupted ring-like formations. Rabbits immunized with these purified recombinant proteins exhibited a strong immune response against the complete VP1 protein. The antisera of these recombinant proteins also reacted positively with the authentic EV71 when analyzed by an immunofluorescence assay thus suggesting their potential as subunit vaccine candidates against EV71 infections and also as immunological reagents for the detection of anti-EV71 antibodies in serum samples.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Master Sains

**PROTEIN NUKLEOKAPSID VIRUS PENYAKIT SAMPAR AYAM SEBAGAI
PEMBAWA POLIPEPTIDA-POLIPEPTIDA VP1 DARIPADA ENTEROVIRUS 71**

Oleh

LALITA AMBIGAI SIVASAMUGHAM

Oktober 2005

Pengerusi: Profesor Datin Khatijah Yusoff, PhD

Fakulti: Bioteknologi dan Sains Biomolekul

Enterovirus 71 (EV71) manusia merupakan sejenis virus manusia yang penting berasal dari genus *Enterovirus* dan famili *Picornaviridae*. Beberapa letusan penyakit yang disebabkan oleh EV71 telah dikaitkan dengan manifestasi penyakit saraf pusat di antaranya ialah penyakit tangan, kaki dan mulut (HFMD). Sehingga kini, tiada ubat yang berkesan untuk merawat jangkitan yang berkaitan. Oleh itu, perkembangan vaksin yang berkesan dianggap sebagai salah satu langkah yang terbaik dalam pencegahan penyakit-penyakit yang disebabkan oleh EV71.

VP1 adalah protein EV71 yang paling immunogenik yang boleh digunakan dalam perkembangan vaksin subunit bagi EV71. Protein VP1 yang lengkap telah dipendekkan kepada enam bahagian dan digabungkan kepada protein nukleokapsid yang lengkap (NPfl) dan protein nukleokapsid protein yang telah dipendekkan (NPt) dari virus penyakit sampar ayam (NDV). Analisis pemblotan

Western dengan menggunakan serum arnab anti-VP1 menunjukkan bahawa bahagian terminal-N protein VP1 mengandungi satu bahagian antigenik yang utama. Daripada kesemua protein-protein rekombinan NP, yang membawa protein VP1, VP1₁₋₁₀₀ merupakan protein yang diekspreskan dengan paling berkesan dalam sistem *Escherichia coli*. Analisis mikroskopik elektron ke atas NPt-VP₁₋₁₀₀ menunjukkan bahawa protein ini membentuk struktur gelang yang sempurna manakala NPfl-VP₁₋₁₀₀ membentuk struktur gelang yang pecah. Arnab-arnab yang diimunitasikan dengan protein-protein rekombinan ini juga telah menunjukkan tindak balas imun yang kuat terhadap protein VP1 yang lengkap. Antiserum protein-protein rekombinan ini juga telah bergerak balas secara positif dengan EV71 yang tulen apabila dianalisis dengan asai imunofloresen lalu mengesyorkan potensi mereka sebagai calon vaksin subunit terhadap penyakit-penyakit EV71 dan juga sebagai reagen imunologik dalam pengesanan antibodi-antibodi anti-EV71 dalam sampel-sampel serum.

ACKNOWLEDGEMENTS

First and foremost, I would like to thank Almighty God for the blessings bestowed upon me throughout the completion of my study and thesis.

I would like to take this opportunity to thank all the wonderful people who have contributed significantly to this study. My most sincere gratitude goes to my supervisors: Prof. Datin Dr. Khatijah Yusoff, for her guidance, trust and the freedom during the entire research and thesis writing; Assoc. Prof. Dr. Tan Wen Siang, for his attentive comments and helpful discussions; Prof. Dr. Mary Jane Cardosa, for her helpful deeds and valuable suggestions. Indeed, without them, this study would have been impossible.

My appreciation also goes to Assoc. Prof. Dr. Fauziah Othman and her staff of the Electron Microscopic Unit of Universiti Putra Malaysia in particular En. Rafiuz Zaman, Puan Faridah, Mr. Ho and Miss Azila for providing me the necessary technical assistance in the electron microscopic analysis. A special thank is also conveyed to the staff and students of the Institute of Health and Community Medicine, Universiti Sarawak Malaysia for their guidance and in making my short visit there a memorable one.

It is also a great pleasure to extend my sincere gratitude to my colleagues; Sing King, Geok Hun, Chiew Ling, Pria, Zul, Onie, Rafidah, Swee Tin, Thong Chuan, Suhana and Eddie for their constant motivation and moral support. I must also

express my deepest thanks to Dr. Majid Eshagi for his useful comments and ideas during the course of the study. Not forgetting the other members of the lab especially Taznim, Salwa, Firoozeh, Andrew, Kah Fai, Yan Peng, Max, Raha and all the others, thank you very much for making my stay in the lab a pleasurable one.

Last but not least, I would like to convey my deepest appreciation to my beloved parents, brother and Prakash for their endless encouragement, inspirations and unconditional love that stood by me all the time.




TABLE OF CONTENTS

		Page
	ABSTRACT	ii
	ABSTRAK	iv
	ACKNOWLEDGEMENTS	vi
	APPROVAL	viii
	DECLARATION	x
	LIST OF TABLES	xiii
	LIST OF FIGURES	xiv
	LIST OF ABBREVIATIONS	xvi
	CHAPTER	
1	INTRODUCTION	1
2	LITERATURE REVIEW	4
	2.1 The EV71 Protein: VP1	4
	2.1.1 The History	4
	2.1.2 Virus Classification	5
	2.1.3 Genomic Organization	6
	2.1.4 Virion Structure	9
	2.1.5 The Replication Cycle	11
	2.1.6 Physical and Chemical Characteristics	13
	2.1.7 Pathogenesis	13
	2.1.8 Prevention, Control and Treatment of EV71 Infections	15
	2.1.8.1 Surveillance and Public Health	15
	2.1.8.2 Antiviral Agents	16
	2.1.8.3 Development of Vaccines	18
	2.1.9 VP1 Protein	21
	2.2 Recombinant Protein as Immunogens	22
	2.3 Protein as A Carrier	23
	2.4 The Molecular Carrier	25
	2.4.1 Newcastle Disease Virus	25
	2.4.2 Nucleocapsid Protein (NP)	25
	2.5 Immune Response	28
3	MATERIALS AND METHODS	31
	3.1 Source of VP1, NPfl and NPt	31
	3.2 Chemicals and Biochemicals	31
	3.3 Constructions of NP Recombinant Proteins	32
	3.3.1 Small Scale Plasmid Extraction	32
	3.3.2 Amplification of Truncated VP1 DNA Fragments	33
	3.3.3 Digestion of Vector and Insert	38

3.3.4	Purification of Vectors and Amplified VP1 Regions	38
3.3.5	Preparation of Competent <i>E. coli</i> TOP10 cells	39
3.3.6	Ligation	39
3.3.7	Screening of Positive Clones	40
3.4	Protein Expression and Solubility Analysis	42
3.4.1	Protein Expression	42
3.4.2	Solubility Analysis	42
3.4.3	SDS-PAGE and Western Blotting	44
3.4.4	Purification of Recombinant Proteins	46
3.4.5	The Bradford Assay	48
3.5	Electron Microscopic Analysis	49
3.6	Immunogenic Analyses	49
3.6.1	Immunization of Rabbits	49
3.6.2	Determination of the Antibody Titers by Indirect ELISA	51
3.6.3	Plaque-Reduction Neutralization Test (PRNT)	52
4	RESULTS	54
4.1	Production of NP Recombinant Proteins	54
4.1.1	Plasmid Miniprep	54
4.1.2	Amplification of Truncated VP1 DNA Fragments	55
4.1.3	Construction of Recombinant Plasmids	55
4.1.4	Expression of Recombinant Proteins	59
4.1.5	Solubility Analysis of NP Recombinant Proteins	66
4.2	Characterisation of NP Recombinant Proteins	67
4.2.1	Purification of NP Recombinant Proteins	67
4.2.2	Self-assembly of Recombinant Proteins into Ring-like Particles	76
4.3	Immunogenic Analyses	76
4.3.1	Indirect ELISA	78
4.3.2	Examination of the Plaque Reduction Assay	80
5	DISCUSSION	81
5.1	Production and Characterisation of NP Recombinant Proteins	81
5.2	Immunogenic Properties of the Ring-like Particles	86
6	CONCLUSION	89
	REFERENCES	92
	APPENDICES	104
	BIODATA OF THE AUTHOR	116

LIST OF TABLES

Table	Page
1 Classification of human enteroviruses according to Pringle (1999)	7
2 Oligonucleotides used for amplifying the specific regions of VP1	36
3 Solubility analysis of recombinant NP proteins produced in <i>E. coli</i> TOP10	69



LIST OF FIGURES

Figure	Page
1 A schematic representation of the enterovirus genome	8
2 Structural features of an enterovirus	10
3 An electron micrograph of purified NP proteins that form ring-like particles when expressed in <i>E. coli</i>	27
4 A schematic diagram depicting pTrcHis2-NPfl/NPt plasmid harbouring the ampicillin resistant gene	35
5 Positions of the oligonucleotides used in amplifying the specific VP1 regions indicated on the complete VP1 gene	37
6 Agarose gel electrophoresis (1.0% w/v) of plasmids harbouring full length NP (NPfl), truncated NP (NPt) coding regions and VP1 DNA fragment	56
7 Schematic representation of truncated VP1 proteins	57
8 Agarose gel electrophoresis (1.0% w/v) of PCR products of the truncated regions of VP1 gene	58
9 Determination of the orientation of the positive clones	60
10 Western blot analysis of the expressed recombinant NP proteins	62
11 Western blot analysis of the expressed NP recombinant proteins	63
12 Western blot analysis of NP recombinant proteins against two different rabbit sera raised against the N-terminal half and the C-terminal half of the VP1 protein	65
13 Solubility analysis of the NP recombinant proteins	68
14 Ammonium sulphate precipitated NP recombinant proteins fractionated in 12% SDS-PAGE and stained with Coomassie Brilliant Blue	71

- 15 Protein sedimentation profiles of NPfl-VP1₁₋₁₀₀ and NPt-VP1₁₋₁₀₀ recombinant proteins 73
- 16 Western blot analysis of the fractionated recombinant NP proteins 74
- 17 The purified and concentrated NP recombinant proteins analyzed in a 12% SDS-PAGE stained with Coomassie Brilliant Blue 75
- 18 Electron micrographs of NPfl-VP1₁₋₁₀₀ and NPt-VP1₁₋₁₀₀ recombinant proteins that form ring-like particles 77
- 19 Determination of antibody titers of anti-NPfl-VP1₁₋₁₀₀ and anti-NPt-VP1₁₋₁₀₀ by indirect ELISA 79



LIST OF ABBREVIATIONS

AFP	acute flaccid paralysis
bp	base pair
β	beta
BCIP	1-bromo-3-chloro-propane
BSA	bovine serum albumin
cDNA	complementary deoxyribonucleic acid
CNS	central nervous system
C-terminus	carboxy terminus
dH ₂ O	distilled water
dNTP	deoxyribonucleic phosphate
DMEM	Dulbecco's Modified Eagle Media
DNA	deoxy-ribonucleic acid
DNase	deoxyribonuclease
DTT	1, 4-dithiothreitol
EDTA	ethylenediamine tetraacetic acid
ELISA	enzyme-linked immunosorbent assay
EV71	Enterovirus 71
F	fusion protein
FCS	fetal calf serum
h	hour
HBV	hepatitis B virus

HBcAg	hepatitis B core antigen
HEPES	n-2-hydroxyethyl-piperazine-n-2-ethanesulfonic acid
HFMD	hand, foot and mouth disease
HN	haemagglutinin-neuraminidase
IgG	immunoglobulin G
IRES	internal ribosome entry site
IPTG	isopropyl- β -D-thiogalactopyranoside
kb	kilobase
kDa	kilodalton
L	large protein
LB	Luria Bertani
μ g	microgram
μ l	microlitre
μ M	micromolar
mA	milliampere
ml	milliliter
mM	millimolar
min	minute
M	molar
NBT	nitro blue tetrazolium
NDV	Newcastle disease virus
ng	nanogram
nm	nanometer

N	normality
NP	nucleocapsid protein
NPfl	full length nucleocapsid protein
NPt	truncated nucleocapsid protein
N-terminus	amino terminus
OD	optical density
ORF	open reading frame
pH	<i>Puissance hydrogene</i>
pTrcHis2-NPfl	pTrcHis2 vector carrying the full length NP
pTrcHis2-NPt	pTrcHis2 vector carrying the truncated NP
P	phosphoprotein
PBS	phosphate-buffer saline
PCR	polymerase chain reaction
rpm	revolutions per minute
RBC	red blood cell
RNA	ribonucleic acid
RNase	ribonuclease
s	seconds
SDS	sodium dodecyl sulphate
SPF	specific pathogen free
TAE	tris-acetate-EDTA buffer
TBS	tris-buffered saline
TCID ₅₀	tissue culture infectious dose

TE	tris-EDTA buffer
U	unit
UTR	untranslated region
UV	ultraviolet
v/v	volume/volume
V	Volt
VLP	virus-like particles
VP1	viral protein 1
VP2	viral protein 2
VP3	viral protein 3
VP4	viral protein 4
VPg	viral protein genomely linked
w/v	weight/volume

CHAPTER 1

INTRODUCTION

Human enterovirus 71 (EV71) belongs to the *Picornaviridae* family and has been noted as one of the causative agents of hand, foot and mouth disease (Chumakov *et al.*, 1979; Nagy *et al.*, 1982; Samuda *et al.*, 1987). The virus enters the host orally via consumption of feecal-contaminated food or water. To date, there is no effective drug treatment or vaccine available for EV71 infections (Shih *et al.*, 2000; Racaniello, 2001; McMinn, 2002). Many clinical and virological similarities between poliovirus and EV71 strongly suggest that the vaccine strategies used against poliovirus can also be adopted to control EV71 infections. As an example, the inactivated poliovirus vaccine (IPV) developed by Jonas Salk was highly effective in reducing the incidence rates of poliomyelitis in 1940s and 1950s (Hull & Aylward, 2001). The same concept was applied to develop an inactivated EV71 vaccine to the Bulgarian epidemic in 1975 but no efficacy data has been obtained (Chumakov *et al.*, 1979). The potential of having virulent revertant virus of live attenuated vaccines (Lin *et al.*, 2002) has made protein-based subunit EV71 vaccine a more favorable choice for vaccine development.

Subunit vaccines are much safer than the inactivated and attenuated vaccines as they cause fewer adverse effects. The isolated subunit protein in a proper conformation can possess neutralizing epitopes. In this regard, two subunit

vaccines were developed based on the immunodominant capsid protein of EV71, VP1 (Wu *et al.*, 2002). The DNA-based vaccine and recombinant protein vaccine were administered to elicit immune response and to protect susceptible newborn mice against lethal EV71 challenge. Both types of vaccines produced similar levels of neutralizing antibodies in the vaccinated dams. With a challenge dose of 230 LD₅₀ per mouse, mice born to dams immunized with the recombinant VP1 protein and DNA vaccine showed 80% survival and 40% survival rates respectively. These findings strongly suggest the potential use of VP1 protein of EV71 for the development of effective subunit EV71 vaccines.

Protein carriers have been extensively studied in the development of subunit vaccines. The use of an appropriate carrier can increase the overall yield, the solubility level as well as the immunogenicity of the recombinant proteins (LaVallie & McCoy, 1995). In relation to this, the nucleocapsid protein (NP) of Newcastle disease virus (NDV) has been demonstrated to be a potential molecular carrier of antigenic proteins (Kho *et al.*, 2001; Rabu *et al.*, 2002). The chimeric NP proteins were expressed as highly soluble and stable proteins in the *E. coli* system. In addition, due to the NP protein, the chimeric proteins were also easily purified by sucrose gradient centrifugation and they readily self-assembled into ring-like particles when viewed under an electron microscope. Furthermore, specific pathogen free (SPF) chickens immunized with these chimeric particles elicited an immune response against NDV, suggesting the possible use of NP as

a carrier for immunogens in the development of subunit vaccines and immunological reagents (Rabu *et al.*, 2002).

In view of this, the objectives of the whole study are first, to construct recombinant NP proteins harbouring the polypeptides of VP1 of EV71. Second, to select recombinant NP proteins that are abundantly expressed in soluble form. Third, to evaluate the potential of these recombinant NP proteins in inducing immune response in animals and lastly, to determine the viral neutralization properties of the antibodies raised against these recombinant proteins.

In order to achieve these objectives, the study begun with the cloning of the truncated VP1 fragments encoding several antigenic polypeptides into an expression vector harbouring the NP coding gene. The recombinant proteins were expressed in *E. coli* cells whereby highly expressed and soluble recombinant proteins were subjected to purification by sucrose gradient ultracentrifugation. Electron microscopic analysis was done to observe the structure of these recombinant proteins. The purified recombinant proteins were then used to immunize rabbits and its antigenicity and the immunogenicity were examined by various methods.

CHAPTER 2

LITERATURE REVIEW

2.1 The EV71 Protein: VP1

2.1.1 The History

Human enterovirus 71 (EV71) was first identified in 1969 in California, following its isolation from an infant suffering from encephalitis (Schmidt *et al.*, 1974). The first isolation of EV71 outside of USA was reported in Melbourne, Australia, during an epidemic of aseptic meningitis between 1972 and 1973 (Kennett *et al.*, 1974). In 1975, this virus gained global attention after an outbreak in Bulgaria that resulted in 705 cases of poliomyelitis-like disease and 44 deaths, with most of these cases involving children under the age of five (Chumakov *et al.*, 1979).

The very first association of EV71 with hand, foot and mouth disease (HFMD), was reported only after small epidemics in both Sweden (Blomberg *et al.*, 1974) and Japan (Gobara *et al.*, 1977; Hagiwara *et al.*, 1978) in 1973. Since then, several large epidemics and high-level endemic circulation have been reported in the Asia-Pacific region. The first such epidemic in Malaysia occurred in Sarawak in 1997 (Cardosa *et al.*, 1999), followed by smaller outbreaks in Japan (Komatsu *et al.*, 1999), Peninsular Malaysia (Lum *et al.*, 1998) and Singapore in 1998

(Singh *et al.*, 2000). These outbreaks were associated with numerous cases of HFMD, herpangina, aseptic meningitis, acute flaccid paralysis (AFP), cerebellar ataxia and even the fatal neurogenic pulmonary oedema (Chang *et al.*, 1999) associated with severe brainstem encephalitis (Chang *et al.*, 1998; Huang *et al.*, 1999).

The largest EV71 epidemic outbreak took place in Taiwan in 1998, with more than 100,000 cases of HFMD being reported (Ho *et al.*, 1999). Subsequently, another large outbreak was also reported in Perth, Australia in 1999 (McMinn *et al.*, 2001). Virological studies were done and both EV71 and Coxsackievirus A16 (CA16) were isolated from these outbreaks but the former was the predominant virus. EV71 continues to circulate in the Asia-Pacific region and in February 2003, the virus was again reported in Sarawak, Malaysia. Most of the cases reported were uncomplicated HFMD but a small number did have neurologic disease (Cardosa *et al.*, 2003).

2.1.2 Virus Classification

Enterovirus 71 belongs to the family *Picornaviridae*, genus *Enterovirus* and the species *Human enterovirus A*. Initially, the original 64 human enterovirus serotypes were grouped into polioviruses (PV), coxsackieviruses A (CA), coxsackieviruses B (CB) and echoviruses (EV) 68 to 71. The major characteristic